药明合联：收入利润强劲增长，在手订单高增长，看好一站式偶联药物CRDMO龙头发展

研究报告 Research Report 23 Aug 2024 药明合联 WuXi XDC Cayman (2268 HK) 24H1：收入利润强劲增长，在手订单高增长，看好一站式偶联药物 CRDMO 龙头发展 24H1: Rapid growth in revenue and profit, abundant backlog in hand, optimistic about one-stop XDC CRDMO leader long-term development | --- | --- | |-----------------------------------------------|---------------------| | [Table_Info] 维持优于大市 Maintain OUTPERFORM | | | 评级 | 优于大市 OUTPERFORM | | 现价 | HK$18.56 | | 目标价 | HK$33.45 | | HTI ESG | 3.3-3.5-4.5 | E-S-G: 0-5, (Please refer to the Appendix for ESG co ...